Table 1 Baseline characteristics, lab characterization at time of serology testing, and CLL-directed therapy history.
From: Anti-SARS-CoV-2 antibody response in patients with chronic lymphocytic leukemia
Characteristic | Proportion, unless otherwise specified (n = 30) |
|---|---|
Baseline characteristics | |
Age at COVID-19 diagnosis, median (range) | 65 (41–82) |
Age at CLL diagnosis, median (range) | 51 (35–76) |
Male | 73% |
CLL-directed therapy history | |
Never treated | 47% |
Current observation | 67% |
Current therapy | 33% |
Current BTKi | 20% |
Prior anti-CD20 monoclonal Ab | 43% |
Prior fludarabine or bendamustine | 30% |
Prior cellular immunotherapy | 3% |
COVID-19 course | |
Required hospital admission | 63% |
Required ICU admission | 36% |
Required oxygen | 50% |
Required intubation | 23% |
Death | 13% |
